24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this crossover trial is to compare the 3-month mean 24-hour
intraocular pressure (IOP) control and safety of dorzolamide/timolol fixed combination (DTFC)
given twice daily, versus latanoprost/timolol fixed combination (LTFC) given in the evening
and placebo given in the morning, versus adjunctive therapy with DTFC given twice daily and
latanoprost 0.005% given once in the evening in open-angle glaucoma patients who are
insufficiently controlled with latanoprost monotherapy.